Navigation Links
Sales of Revlimid and the Launch of Several Premium-Priced Emerging Therapies Will Drive Robust 7.2 Percent Annual Growth in the Multiple Myeloma Drug Market
Date:12/6/2010

BURLINGTON, Mass., Dec. 6, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of Celgene's Revlimid in the first-line setting and the launch of several premium-priced emerging therapies will drive robust 7.2 percent annual growth through 2019 in the multiple myeloma drug market.

The Pharmacor 2010 findings from the topic entitled Multiple Myeloma which will publish later this month reveal that although the first-line setting is currently dominated by Takeda/Janssen-Cilag/Janssen's Velcade in terms of patient and market share, sales of Velcade will be rapidly eclipsed by the dramatic growth of Revlimid. The findings also reveal that sales of Celgene's Thalidomide/Thalomid and Fujimoto Seiyaku's Thaled will be more aggressively eroded compared with Velcade, owing to the approval of Revlimid in the first-line setting.

Sales of both Revlimid and Velcade will also increase in the relapsed/refractory setting, despite the entrance of novel emerging therapies such as Celgene's pomalidomide and Onyx Pharmaceuticals/Ono Pharmaceutical's carfilzomib. Revlimid will be used in combination with carfilzomib, while Velcade will experience increased uptake in the relapsed/refractory setting in combination with other emerging agents such as Keryx Biopharmaceuticals/AEterna Zentaris's perifosine, Merck's Zolinza and Novartis's panobinostat.

"The most commercially promising emerging therapies in development -- pomalidomide and carfilzomib -- belong to the same drug classes as the highly successful currently available therapies, but these two agents will struggle to attain the same market share as well-established agents," said Decision Resources Analyst Andrew Merron, Ph.D. "Other promising emerging agents such as perifosine, Zolinza and panobinostat will introduce novel mechanisms of action into the myeloma treatment paradigm."  

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com .

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Commences U.S. Sales of Unitract® 1mL Syringes
2. RF Technologies® Names Paul Reynard Senior Vice President-Sales and Service
3. Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion
4. Decline in Pharmaceutical Sales in The Cape Coral, Fla. Market Due to High Uninsurance Rates and Generic Utilization Will Be Offset by the Establishment of High-Risk Pool and Medical Homes
5. Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations
6. Yondelis(R) Sales Expanded by 70 Percent
7. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
8. Decision Resources Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
9. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
10. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Executive Summary ... primary research (inputs from industry experts, companies, stakeholders) ... the analysis of global heart valve devices market ... Replacement Procedure By Technique (Mechanical, Bioprosthetic, Transcatheter Aortic ... Balloon Valvuloplasty, Transcatheter Mitral Valve Repair (TMVR)), By ...
(Date:3/23/2017)... As a result of diagnostic technology ... of allergic diseases, cutting edge developments in targeted ... ways in which pharmaceutical and biotech companies are ... be both a high quality meeting and a ... immunologists, research scholars and doctors. The event will ...
(Date:3/23/2017)... LONDON , March 23, 2017 ... latest Pharmaceutical and Healthcare disease pipeline guide Primary ... overview of the Primary Hyperoxaluria (Genito Urinary System ... is a rare condition characterized by recurrent kidney ... of a substance called oxalate. Symptoms include blood ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming of ... creation of published author, Wesley Gerboth, a World War II veteran, with a highly-regarded ... at age ninety-one, he shares the Wisdom God bestowed upon him in this publication. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: A ... God in congregations across the United States. “The Communion of Saints” is ... who has served congregations in seven states throughout his long career of devotion ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization ... could be four million Zika-related cases in the Americas within the next year. Lyme ... cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other ...
(Date:3/23/2017)... ... , ... The physicians of KSF Orthopaedic Center PA are proud to announce ... is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside ... patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... Texas ... located at 960 Gruene Road in Building 2. The clinic is the group’s second ... Bennett, PT, says opening the company’s second New Braunfels location brings things full circle ...
Breaking Medicine News(10 mins):